Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 134

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 134
---
 attention from our business. We will need additional capital, and any inability to obtain such additional capital and on acceptable terms may limit our ability to execute our business plan and our ability to develop and expand our operations. If we issue additional shares or equity -linked instruments, our then existing shareholders may experience dilution, which may be substantial. Our audited combined financial statements for the year ended June 30, 2024 state that substantial doubt exists about our ability to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and our investors may receive less than the value at which those assets are carried on our financial statements, and may suffer the loss of all or a part of their investment. In addition, we will require additional capital to fully fund our current strategic plan, which includes continuing to scale our genetic tests in Latin America, and developing a pipeline of future products and services and artificial intelligence technology. Additional financing may not be available in amounts or on terms satisfactory to us or at all. Our success in raising additional capital may be significantly affected by general market conditions, the market price of our ordinary shares, our financial condition, uncertainty about the future commercial success of our current products and services, the development and commercial success of future products or services, regulatory developments, the status and scope of our intellectual property, any ongoing litigation, our compliance with applicable laws and regulations and other factors. If we raise additional funds through the sale of equity, convertible debt or other equity -linkedsecurities, our shareholders’ ownership will be diluted, and the market price of our ordinary shares could be depressed. We may issue securities that have rights, preferences and privileges senior to our ordinary shares. If we raise additional funds through collaborations, licensing arrangements or other structured financing transactions, we may relinquish rights to our technologies or products or services, grant security interests in our assets or grant licenses to third parties on terms that are unfavorable to us. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire companies or acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our ordinary shares to decline. In the event we enter into collaborations or